- Home
- DFIN vs JANX Comparison
DFIN vs JANX Comparison
Compare DFIN & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFIN
- JANX
- Stock Information
- Founded
- DFIN 1983
- JANX 2017
- Country
- DFIN United States
- JANX United States
- Employees
- DFIN N/A
- JANX N/A
- Industry
- DFIN Other Consumer Services
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- DFIN Consumer Discretionary
- JANX Health Care
- Exchange
- DFIN Nasdaq
- JANX Nasdaq
- Market Cap
- DFIN 1.8B
- JANX 1.4B
- IPO Year
- DFIN N/A
- JANX 2021
- Fundamental
- Price
- DFIN $54.25
- JANX $25.11
- Analyst Decision
- DFIN Strong Buy
- JANX Strong Buy
- Analyst Count
- DFIN 3
- JANX 8
- Target Price
- DFIN $68.67
- JANX $90.63
- AVG Volume (30 Days)
- DFIN 312.6K
- JANX 895.9K
- Earning Date
- DFIN 07-31-2025
- JANX 08-07-2025
- Dividend Yield
- DFIN N/A
- JANX N/A
- EPS Growth
- DFIN N/A
- JANX N/A
- EPS
- DFIN 2.79
- JANX N/A
- Revenue
- DFIN $755,000,000.00
- JANX $439,000.00
- Revenue This Year
- DFIN $1.91
- JANX N/A
- Revenue Next Year
- DFIN $4.64
- JANX $1,470.83
- P/E Ratio
- DFIN $19.89
- JANX N/A
- Revenue Growth
- DFIN N/A
- JANX N/A
- 52 Week Low
- DFIN $37.80
- JANX $21.97
- 52 Week High
- DFIN $70.55
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- DFIN 42.43
- JANX 53.07
- Support Level
- DFIN $51.18
- JANX $23.96
- Resistance Level
- DFIN $58.45
- JANX $25.93
- Average True Range (ATR)
- DFIN 2.61
- JANX 1.55
- MACD
- DFIN -0.04
- JANX 0.08
- Stochastic Oscillator
- DFIN 26.94
- JANX 69.31
About DFIN Donnelley Financial Solutions Inc.
Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.